Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Sarcoma, Synovial 2Liposarcoma, Myxoid 2Sezary Syndrome 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 5avelumab 4Ipilimumab 4Radiotherapy 2Radiosurgery 2ALT-803 2tremelimumab 1talimogene laherparepvec 1sapanisertib 1prednylidene 1poly ICLC 1lenvatinib 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1deltacortene 1cemiplimab 1cabozantinib 1bempegaldesleukin 1atezolizumab 1Tacrolimus 1Radiation Dose Hypofractionation 1Radiation 1Prednisone 1Interferon-gamma 1Interferon-beta 1CTLA-4 Antigen 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Merkel Cell × Interferon-gamma × Clear all
NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
7 enrolled 15 charts
Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡